| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18579811 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 125 journal articles in the PubMed database | Email to a friend | | |
| Eriksson BI, Borris LC, Friedman RJ, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. [Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
N Engl J Med 2008 Jun 26; 358(26):2765-75.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Lassen MR, Ageno W, Borris LC, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. [Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
N Engl J Med 2008 Jun 26; 358(26):2776-86.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Kakkar AK, Brenner B, Dahl OE, et al.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. [Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
Lancet 2008 Jul 5; 372(9632):31-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Eriksson BI, Borris LC, Dahl OE, et al.
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. [Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
Circulation 2006 Nov 28; 114(22):2374-81.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Fisher WD, Eriksson BI, Bauer KA, et al.
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. [Journal Article]
Thromb Haemost 2007 Jun; 97(6):931-7.
Abstract | Full Citation | Find Related Articles | | Eriksson BI, Borris LC, Dahl OE, et al.
Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. [JOURNAL ARTICLE]
Thromb Res 2007 Feb 9.
Abstract | Full Citation | | Eriksson BI, Borris L, Dahl OE, et al.
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. [Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2006 Jan; 4(1):121-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Turpie AG, Fisher WD, Bauer KA, et al.
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. [Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2005 Nov; 3(11):2479-86.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Agnelli G, Gallus A, Goldhaber SZ, et al.
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. [Journal Article, Research Support, Non-U.S. Gov't]
Circulation 2007 Jul 10; 116(2):180-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
